For the Inventor, By the Inventor

Enter assignee name

Migdal Haemeq, Israel

Enzymotec Ltd.

USPTO Granted Patents = 29

% Expired Patents = 13.8

CIPO Patents = 7

EPO Patents = 13

Trademarks = 4

Forward Citations = 82

Loading Chart...

Loading Chart...

36 inventors (with patents filed for the assignee):

Avidor Shulman (17 out of 19 patents)

Gai Ben Dror (17 out of 18 patents)

Dori Pelled (13 out of 18 patents)

4. Rassan Zuabi (12 out of 13 patents)

5. Zohar Bar-On (11 out of 12 patents)

6. Orly Farkash (9 out of 10 patents)

7. Yael Herzog (7 out of 8 patents)

8. Yael Richter (7 out of 8 patents)

9. Dorit Platt (6 out of 7 patents)

10. Yael Lifshitz (6 out of 6 patents)

11. Tzafra Cohen (5 out of 8 patents)

12. Dorit Plat (4 out of 4 patents)

13. Asher Widberg (3 out of 4 patents)

14. Fabiana Bar-Yoseph (3 out of 3 patents)

15. Hala Laouz (3 out of 3 patents)

Core Competencies:

Phosphatidylserine

Glycerophospholipids

Nutritional Compositions

Cognitive Functions

Human Milk Fat

Oil Blends

Gut Flora Development

Omega-3 Fatty Acids

Intestinal Maturation

Fatty Acid Esters

Lipid Compositions

Phytosterol Esters

29 patents: Sort by Forward Citations

1. 12708636 - NUTRITIONAL COMPOSITIONS CONTAINING PHOSPHATIDYLSERINE POWDER (2026-08-18),

2. 10993456 - Oil blends, processes for the preparation thereof and their use in formulas (2021-05-04),

3. 10894056 - Phospholipid preparations for the improvement of sleep (2021-01-19),

4. 10888573 - Phospholipid preparations for the improvement of brain plasticity (2021-01-12),

5. 10688070 - Serine glycerophospholipid preparation and method for treatment of seizures (2020-06-23),

6. 10004247 - Process for the preparation of human milk fat substitutes (2018-06-26),

7. 9962455 - Glycerophospholipids for the improvement of cognitive functions (2018-05-08),

8. 9814252 - Polar lipid mixtures, their preparation and uses (2017-11-14),

9. 9585966 - Glycerophospholipids for the improvement of cognitive functions (2017-03-07),

10. 9561207 - Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation (2017-02-07),

11. 9433599 - Methods and lipid compositions for promoting development of gut flora (2016-09-06),

12. 9332771 - Human milk fat substitutes (2016-05-10),

13. 9282748 - Human breast milk lipid mimetic as a dietary supplement (2016-03-15),

14. 9168310 - Glycerophospholipids for the improvement of cognitive functions (2015-10-27),

15. 9107439 - Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation (2015-08-18),

Company Overview

Enzymotec Ltd. is a biotechnology company based in Migdal Haemeq, Israel, specializing in the development and manufacturing of innovative nutritional products and dietary supplements. The company focuses on advanced lipid technologies and bioactive compounds, aiming to enhance health and wellness through its research-driven approach. Enzymotec's expertise spans various domains, including infant nutrition, medical nutrition, and functional foods, positioning it as a key player in the global health and nutrition market.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

29 Patents

#1 in Migdal Haemeq

#204 in Israel

#22,570 in the World

Migdal Haemeq, Israel

Enzymotec Ltd.

Forward Citations = 82

36 inventors:

Avidor Shulman (17 out of 19 patents)

Gai Ben Dror (17 out of 18 patents)

Dori Pelled (13 out of 18 patents)

4. Rassan Zuabi (12 out of 13 patents)

5. Zohar Bar-On (11 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Enzymotec Ltd.. Retrieved from https://idiyas.com/company/enzymotec

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…